The latest news in technology and science from Protagenic
(This paper was highlighted on the cover on the journal)
Protagenic Therapeutics, Inc. hosted a scientific webinar reviewing its programs designed for the treatment of patients with Depression, PTSD, Anxiety and Addiction.
The webinar features presentations by scientific founder David Lovejoy, PhD; PTI Chief Operating Officer Andrew Slee, PhD; and its Chief Medical Officer Robert Stein, MD, PhD.
In addition, the company provided an update on PT00114’s upcoming clinical program, including the structure of the anticipated Phase I/IIa multi-center clinical trial.
Protagenic Therapeutics, Inc.’s key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction.
The webinar features a presentation by KOL Dr. Maurizio Fava, Massachusetts General Hospital (MGH), who is serving as principal investigator in Protagenic’s upcoming Phase 1/2a clinical trial.
Protagenic’s management team also provided an overview of the ongoing clinical development program and potential commercial opportunity for PT00114, which is known scientifically as teneurin C-terminal associated peptide (TCAP), a naturally occurring peptide responsible for regulation of stress response in the brain.
Psychedelics in Psychiatry and Beyond
© 2022 Protagenic Therapeutics, Inc.
Built by Techtegic